$591.90

-0.94 (-0.16%)

Weekly Expected Move ±8.0%

$494 $541 $588 $634 $681

NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 72 · $25.4B mcap · 39M float · 1.68% daily turnover · Short 71% of daily vol

Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾

Not rated: no debt. Altman Z'' 16.42.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$3.2B +10.6% ▲

5Y CAGR: +16.5%

Gross Profit

$2.8B +9.0% ▲

5Y CAGR: +15.3%

Operating Income

$1.5B +8.4% ▲

5Y CAGR: +20.2%

Net Income

$1.3B +11.7% ▲

5Y CAGR: +21.0%

EPS (Diluted)

$27.86 +13.1% ▲

5Y CAGR: +19.3%

EBITDA

$1.8B +9.9% ▲

5Y CAGR: +23.0%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.7B	$1.9B	$2.3B	$2.9B	$3.2B
YoY Growth	+13.6%	+14.9%	+20.2%	+23.6%	+10.6%
Cost of Revenue	$122M	$147M	$258M	$310M	$384M
Gross Profit	$1.6B	$1.8B	$2.1B	$2.6B	$2.8B
Gross Margin	92.7%	92.4%	88.9%	89.2%	87.9%
R&D Expenses	$540M	$323M	$408M	$481M	$550M
SG&A Expenses	$467M	$487M	$477M	$639M	$756M
Operating Expenses	$1.0B	$810M	$885M	$1.2B	$1.3B
Operating Income	$556M	$980M	$1.2B	$1.4B	$1.5B
Operating Margin	33.0%	50.6%	50.9%	47.9%	46.9%
Interest Expense	$19M	$32M	$59M	$43M	$20M
Income Before Tax	$594M	$951M	$1.3B	$1.5B	$1.7B
Tax Expense	$118M	$223M	$290M	$344M	$379M
Net Income	$476M	$727M	$985M	$1.2B	$1.3B
Net Margin	28.2%	37.6%	42.3%	41.5%	41.9%
EPS (Diluted)	$10.06	$15.00	$19.81	$24.64	$27.86
EBITDA	$737M	$1.0B	$1.4B	$1.7B	$1.8B
Shares Outstanding	47M	48M	50M	48M	48M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$749M	$736M	$794M	$799M	$800M	$790M	$782M	$783M
Cost of Revenue	$83M	$76M	$92M	$88M	$101M	$103M	$133M	$100M
Gross Profit	$666M	$660M	$702M	$711M	$699M	$687M	$648M	$684M
Gross Margin	88.9%	89.7%	88.4%	89.0%	87.4%	86.9%	82.9%	87.3%
R&D Expenses	$104M	$134M	$149M	$134M	$128M	$140M	$138M	$146M
SG&A Expenses	$219M	$162M	$170M	$191M	$183M	$190M	$184M	$175M
Operating Expenses	$323M	$302M	$319M	$346M	$310M	$329M	$322M	$353M
Operating Income	$343M	$358M	$383M	$364M	$388M	$358M	$326M	$331M
Operating Margin	45.8%	48.6%	48.2%	45.6%	48.6%	45.2%	41.7%	42.2%
Interest Expense	$10M	$8M	$6M	$7M	$3M	$3M	$3M	$3M
Income Before Tax	$389M	$396M	$424M	$408M	$438M	$444M	$318M	$373M
Tax Expense	$80M	$95M	$101M	$99M	$99M	$80M	$43M	$40M
Net Income	$309M	$301M	$322M	$310M	$339M	$364M	$275M	$333M
Net Margin	41.3%	40.9%	40.6%	38.8%	42.4%	46.1%	35.2%	42.5%
EPS (Diluted)	$6.39	$6.19	$6.63	$6.41	$7.16	$7.66	$5.82	$7.27
EBITDA	$418M	$424M	$383M	$437M	$463M	$470M	$344M	$400M
Shares Outstanding	48M	49M	49M	48M	47M	48M	47M	46M

UTHR NASDAQ